MCID: ARG006
MIFTS: 26

Aregenerative Anemia

Categories: Blood diseases, Rare diseases

Aliases & Classifications for Aregenerative Anemia

MalaCards integrated aliases for Aregenerative Anemia:

Name: Aregenerative Anemia 55 69
Refractory Anemias 69

Classifications:



External Ids:

Orphanet 55 ORPHA101096
UMLS via Orphanet 70 C0553669 C0002893
ICD10 via Orphanet 33 D46.7

Summaries for Aregenerative Anemia

MalaCards based summary : Aregenerative Anemia, also known as refractory anemias, is related to diamond-blackfan anemia 1 and ghosal hematodiaphyseal dysplasia. An important gene associated with Aregenerative Anemia is TBXAS1 (Thromboxane A Synthase 1). The drugs Iron and Deferasirox have been mentioned in the context of this disorder. Affiliated tissues include myeloid, bone and bone marrow.

Related Diseases for Aregenerative Anemia

Diseases related to Aregenerative Anemia via text searches within MalaCards or GeneCards Suite gene sharing:

# Related Disease Score Top Affiliating Genes
1 diamond-blackfan anemia 1 11.2
2 ghosal hematodiaphyseal dysplasia 11.1
3 diamond-blackfan anemia 11.1
4 thymoma, familial 10.2
5 thymoma 10.2
6 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 9.9
7 leukemia 9.9
8 pancytopenia 9.9
9 monocytic leukemia 9.9
10 refractory anemia 9.9

Graphical network of the top 20 diseases related to Aregenerative Anemia:



Diseases related to Aregenerative Anemia

Symptoms & Phenotypes for Aregenerative Anemia

Drugs & Therapeutics for Aregenerative Anemia

Drugs for Aregenerative Anemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 233)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Iron Approved Phase 4,Phase 2,Phase 3 7439-89-6 23925
2
Deferasirox Approved, Investigational Phase 4,Phase 2 201530-41-8 5493381
3 Chelating Agents Phase 4,Phase 1,Phase 2
4 Iron Chelating Agents Phase 4,Phase 2
5
Dopamine Approved Phase 3 51-61-6, 62-31-7 681
6
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 2 50-02-2 5743
7
Mitoxantrone Approved, Investigational Phase 3,Phase 2,Phase 1 65271-80-9 4212
8
Daunorubicin Approved Phase 2, Phase 3, Phase 1 20830-81-3 30323
9
Etoposide Approved Phase 2, Phase 3, Phase 1 33419-42-0 36462
10
Idarubicin Approved Phase 2, Phase 3, Phase 1 58957-92-9 42890
11
Cytarabine Approved, Investigational Phase 2, Phase 3, Phase 1 147-94-4 6253
12
Fludarabine Approved Phase 2, Phase 3, Phase 1 21679-14-1, 75607-67-9 30751
13
Metoclopramide Approved, Investigational Phase 3 364-62-5 4168
14
Prednisolone Approved, Vet_approved Phase 2, Phase 3, Phase 1 50-24-8 5755
15
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 22916-47-8 4189
16 Thiotepa Approved, Investigational Phase 2, Phase 3,Phase 1 52-24-4 5453
17
Lenograstim Approved, Investigational Phase 3,Phase 2,Phase 1 135968-09-1
18
Methylprednisolone Approved, Vet_approved Phase 2, Phase 3, Phase 1 83-43-2 6741
19
Darbepoetin alfa Approved, Investigational Phase 3,Phase 2 209810-58-2, 11096-26-7
20
Azacitidine Approved, Investigational Phase 3,Phase 2,Phase 1 320-67-2 9444
21
Arsenic trioxide Approved, Investigational Phase 2, Phase 3,Phase 1 1327-53-3 518740
22
Decitabine Approved, Investigational Phase 3,Phase 2,Phase 1 2353-33-5 451668
23 Magnesium citrate Approved Phase 3
24
Tacrolimus Approved, Investigational Phase 2, Phase 3,Phase 1 104987-11-3 445643 439492
25
Methotrexate Approved Phase 3,Phase 2,Phase 1 1959-05-2, 59-05-2 126941
26
Amsacrine Approved, Investigational Phase 3 51264-14-3 2179
27
Melphalan Approved Phase 2, Phase 3, Phase 1 148-82-3 460612 4053
28
Carboplatin Approved Phase 2, Phase 3,Phase 1 41575-94-4 10339178 38904 498142
29
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1 50-18-0, 6055-19-2 2907
30
Hydroxyurea Approved Phase 3 127-07-1 3657
31
Busulfan Approved, Investigational Phase 3,Phase 2,Phase 1 55-98-1 2478
32
Hydrocortisone Approved, Vet_approved Phase 3 50-23-7 657311 5754
33
alemtuzumab Approved, Investigational Phase 2, Phase 3,Phase 1 216503-57-0
34
Clofarabine Approved, Investigational Phase 2, Phase 3 123318-82-1 119182
35
Benzocaine Approved, Investigational Phase 3,Phase 2,Phase 1 1994-09-7, 94-09-7 2337
36
Thioguanine Approved Phase 3 154-42-7 2723601
37
Asparaginase Approved, Investigational Phase 3 9015-68-3
38
Aldesleukin Approved Phase 3,Phase 1,Phase 2 110942-02-4, 85898-30-2
39
Octreotide Approved, Investigational Phase 2, Phase 3 83150-76-9 6400441 383414
40
Somatostatin Approved, Investigational Phase 2, Phase 3 38916-34-6, 51110-01-1 53481605
41
Citric Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 1,Phase 2 77-92-9 311
42
leucovorin Approved, Nutraceutical Phase 3,Phase 2,Phase 1 58-05-9 143 6006
43 tannic acid Approved, Nutraceutical Phase 3,Phase 2,Phase 1
44
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1 59-30-3 6037
45
Tretinoin Approved, Investigational, Nutraceutical Phase 3,Phase 1,Phase 2 302-79-4 5538
46
tipifarnib Investigational Phase 2, Phase 3,Phase 1 192185-72-1 159324
47
Butyric Acid Experimental, Investigational Phase 3 107-92-6 264
48 Prednisolone acetate Phase 2, Phase 3, Phase 1
49 Dexamethasone acetate Phase 3,Phase 2 1177-87-3
50 Analgesics Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 203)

# Name Status NCT ID Phase Drugs
1 Efficacy and Safety of Deferasirox in Patients With Myelodysplastic Syndrome and Transfusion-dependent Iron Overload Completed NCT00481143 Phase 4 ICL670/Deferasirox
2 Bowel Preparation and Prokinetics in Capsule Endoscopy Unknown status NCT00275184 Phase 3 Senna;Citramag powder;Metoclopramide
3 Treatment of Adults Aged Up to 60 Years With De Novo Acute Myeloblastic Leukaemia,Secondary AML, or RAEB-T Unknown status NCT00209833 Phase 2, Phase 3 Cytarabine;Idarubicin;Etoposide;Fludarabine;G-CSF;Daunorubicine
4 Comparison Study of Standard Care Against Combination of Growth Factors Agents for Low-risk Myelodysplastic Syndromes Unknown status NCT01196715 Phase 3 Darbepoetin alpha;Filgrastim
5 Erythropoietin (EPO) and Granulocyte-Colony Stimulating Factor (G-CSF) for Low-Risk Myelodysplastic Syndromes (MDS) Unknown status NCT00234143 Phase 2, Phase 3 Darbepoetin
6 Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Myelodysplastic Syndrome or Acute Myelogenous Leukemia Unknown status NCT00002926 Phase 3 cytarabine;etoposide;idarubicin
7 Combination Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia Unknown status NCT00003602 Phase 3 cytarabine;etoposide;idarubicin;mitoxantrone hydrochloride
8 Low-Dose Decitabine Compared With Standard Supportive Care in Treating Older Patients With Myelodysplastic Syndrome Unknown status NCT00043134 Phase 3 decitabine
9 Daunorubicin & Cytarabine +/- Zosuquidar inTreating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or Refractory Anemia Completed NCT00046930 Phase 3 cytarabine;daunorubicin hydrochloride;zosuquidar trihydrochloride;Placebo
10 Cytarabine and Daunorubicin With or Without Gemtuzumab Ozogamicin in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes Completed NCT00121303 Phase 3 cytarabine;daunorubicin hydrochloride;gemtuzumab ozogamicin
11 Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myelogenous Leukemia or Myelodysplastic Syndrome Completed NCT00002798 Phase 3 asparaginase;daunorubicin hydrochloride;fludarabine phosphate;therapeutic hydrocortisone;cytarabine;idarubicin;dexamethasone;thioguanine;etoposide;methotrexate;cyclophosphamide;busulfan
12 Antithymocyte Globulin and Cyclosporine in Treating Patients With Myelodysplastic Syndrome Completed NCT00004208 Phase 3 ATG + CSA
13 Erythropoietin (EPO)+/- Filgrastim (G-CSF) vs. Supportive Therapy Alone for Patients With Myelodysplastic Syndromes Completed NCT00003138 Phase 3
14 Sibling Donor Peripheral Stem Cell Transplant or Sibling Donor Bone Marrow Transplant in Treating Patients With Hematologic Cancers or Other Diseases Completed NCT00438958 Phase 3
15 Bone Marrow Transplantation in Treating Patients With Leukemia, Myelodysplasia, or Lymphoblastic Lymphoma Completed NCT00003187 Phase 2, Phase 3 cyclophosphamide;cyclosporine;cytarabine;methotrexate;methylprednisolone
16 Chemotherapy in Treating Children With Down Syndrome and Myeloproliferative Disorder, Acute Myelogenous Leukemia, or Myelodysplastic Syndrome Completed NCT00003593 Phase 3 asparaginase;cytarabine;daunorubicin hydrochloride;methotrexate;therapeutic hydrocortisone;thioguanine
17 S9920 Busulfan Compared With Cyclophosphamide in Patients Undergoing Total-Body Irradiation Plus Peripheral Stem Cell Transplantation for Advanced Myelodysplastic Syndrome or Related Acute Myeloid Leukemia Completed NCT00005866 Phase 3 busulfan;cyclophosphamide;cyclosporine;methotrexate
18 Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myeloid Leukemia Completed NCT00003436 Phase 3 amsacrine;asparaginase;cytarabine;daunorubicin hydrochloride;etoposide;methotrexate;mitoxantrone hydrochloride;therapeutic hydrocortisone
19 Treatment of Bone Marrow to Prevent Graft-Versus-Host Disease in Patients With Acute or Chronic Leukemia Undergoing Bone Marrow Transplantation Completed NCT00004255 Phase 2, Phase 3 cyclophosphamide;fludarabine phosphate;methylprednisolone;tacrolimus
20 Intensive Compared With Nonintensive Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Completed NCT00005823 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;hydroxyurea;idarubicin;mitoxantrone hydrochloride;thioguanine;tretinoin;valspodar
21 Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome Completed NCT00002517 Phase 3 cytarabine;daunorubicin hydrochloride;dexamethasone;etoposide;idarubicin;mitoxantrone hydrochloride;thioguanine
22 Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes Completed NCT00454480 Phase 2, Phase 3 arsenic trioxide;azacitidine;busulfan;clofarabine;cytarabine;daunorubicin hydrochloride;fludarabine phosphate;gemtuzumab ozogamicin;melphalan;tipifarnib
23 Efficacy of Octreotide on Blood and Iron Requirements in Patients With Anaemia Due to Angiodysplasias Recruiting NCT02384122 Phase 2, Phase 3 Octreotide
24 G-CSF+Decitabine+BUCY vs BUCY Conditioning Regimen for RAEB-1, REAB-2 and AML Secondary to MDS Undergoing Allo-HSCT Recruiting NCT02744742 Phase 2, Phase 3 Decitabine;Busulfan (BU);Cyclophosphamide (CY);Granulocyte Colony-Stimulating Factor(G-CSF)
25 Controlled Study of Rigosertib Versus Physician's Choice of Treatment in MDS Patients After Failure of an HMA Recruiting NCT02562443 Phase 3 rigosertib;Any approved or standard-of-care therapy;best supportive care (BSC);best supportive care (BSC)
26 Efficacy and Safety of IV Rigosertib in MDS Patients With Excess Blasts Progressing After Azacitidine or Decitabine Active, not recruiting NCT01928537 Phase 3 rigosertib sodium
27 Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer Active, not recruiting NCT00003816 Phase 2, Phase 3 busulfan;carboplatin;cyclophosphamide;etoposide;fludarabine phosphate;melphalan;thiotepa
28 A Randomized Study of Post-Remission Therapy in Elderly Patients With Acute Myelogenous Leukemia. Terminated NCT00363025 Phase 3 Idarubicin versus daunorubicin
29 Safety and Efficacy Study of Umbilical Cord/Placenta-Derived Mesenchymal Stem Cells to Treat Myelodysplastic Syndromes Unknown status NCT01129739 Phase 2
30 Amifostine in Treating Patients With Advanced Myelodysplastic Syndrome Unknown status NCT00003123 Phase 2 amifostine trihydrate
31 Antithymocyte Globulin Compared With Supportive Care in Treating Patients With Myelodysplastic Syndrome Unknown status NCT00017550 Phase 2
32 Gemtuzumab in Treating Patients With Myelodysplastic Syndrome Unknown status NCT00022321 Phase 2 gemtuzumab ozogamicin
33 Combination Chemotherapy in Treating Patients With Myelodysplastic Syndrome Unknown status NCT00003827 Phase 2 amifostine trihydrate;cytarabine;topotecan hydrochloride
34 Vaccine Therapy and GM-CSF in Treating Patients With Low-Risk or Intermediate-Risk Myelodysplastic Syndrome Unknown status NCT00513578 Phase 2
35 Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes Unknown status NCT00020969 Phase 2 arsenic trioxide
36 Amifostine With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome Unknown status NCT00003681 Phase 2 amifostine trihydrate
37 Bexarotene and GM-CSF in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia Unknown status NCT00425477 Phase 2 bexarotene
38 Amifostine and High-Dose Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia or Chronic Myelogenous Leukemia Unknown status NCT00003407 Phase 2 amifostine trihydrate;cytarabine;mitoxantrone hydrochloride
39 Study of 72-Hour Infusion of ON 01910.Na in Patients With MDS or AML Completed NCT00854945 Phase 1, Phase 2 ON 01910.Na
40 A Randomized Trial of Antithymocyte Globulin Versus Cyclosporine to Treat the Cytopenia of Myelodysplastic Syndrome Completed NCT00001839 Phase 2 Antithymocyte globulin;Cyclosporine
41 Allogeneic Bone Marrow Transplantation With Matched Unrelated Donors for Patients With Hematologic Malignancies Completed NCT00208923 Phase 2 Busulfan, Cyclophosphamide and Fludarabine
42 Liposomal Daunorubicin and SU5416 in Treating Patients With Hematologic Cancer That Has Not Responded to Initial Therapy Completed NCT00005942 Phase 1, Phase 2 liposomal daunorubicin citrate;semaxanib
43 Azacitidine Plus Amifostine in Treating Patients With Myelodysplastic Syndrome Completed NCT00005598 Phase 2 amifostine trihydrate;azacitidine
44 Safety and Tolerability Trial of Abatacept-based Immunosuppression for Prevention of Acute GvHD During Unrelated Donor Hematopoietic Stem Cell Transplant Completed NCT01012492 Phase 2 Abatacept
45 Thalidomide in Treating Patients With Myelodysplastic Syndrome Completed NCT00015990 Phase 2 thalidomide
46 Differentiation Therapy With Decitabine in Treating Patients With Myelodysplastic Syndrome Completed NCT01165996 Phase 1, Phase 2 decitabine
47 Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies Completed NCT01789255 Phase 2 vorinostat;tacrolimus;cyclosporine;methotrexate
48 Infusion of Off-the-Shelf Expanded Cord Blood Cells to Augment Cord Blood Transplant in Patients With Hematologic Malignancies Completed NCT01175785 Phase 2 fludarabine phosphate;cyclophosphamide;cyclosporine;mycophenolate mofetil
49 Amifostine Plus Topotecan in Treating Patients With Myelodysplastic Syndrome Completed NCT00003415 Phase 1, Phase 2 amifostine trihydrate;topotecan hydrochloride
50 MS-275 and GM-CSF in Treating Patients With Myelodysplastic Syndrome and/or Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphocytic Leukemia Completed NCT00462605 Phase 2 entinostat;sargramostim

Search NIH Clinical Center for Aregenerative Anemia

Genetic Tests for Aregenerative Anemia

Anatomical Context for Aregenerative Anemia

MalaCards organs/tissues related to Aregenerative Anemia:

38
Myeloid, Bone, Bone Marrow, Kidney, T Cells, Endothelial, Testes

Publications for Aregenerative Anemia

Articles related to Aregenerative Anemia:

(show all 11)
# Title Authors Year
1
Immune aregenerative anemia without erythroblastopenia: a previously undescribed condition. ( 23408098 )
2013
2
Thymoma and aregenerative anemia. ( 3420452 )
1988
3
Bone marrow transplantation: cellular engineering to correct primary immunodeficiency, aregenerative anemia and pancytopenia. ( 238679 )
1975
4
The effectiveness of splenectomy in the treatment of aregenerative anemia. Aplastic and hypoplastic anemia. ( 4807706 )
1973
5
Refractory anemia with hyperplastic bone marrow (aregenerative anemia). ( 4864460 )
1967
6
THE SYNDROME OF BENIGN THYMOMA AND PRIMARY AREGENERATIVE ANEMIA; AN ANALYSIS OF FORTY-THREE CASES. ( 14169820 )
1964
7
Refractory aregenerative anemia and benign thymoma treated by thymectomy with remission. ( 14023694 )
1963
8
Elective thymectomy in the treatment of aregenerative anemia associated with monocytic leukemia. ( 13833083 )
1960
9
Aregenerative anemia associated with benign thymoma. ( 13566459 )
1958
10
Splenectomy for pure red-cell hypoplastic (aregenerative) anemia associated with autoimmune hemolytic disease; report of a case. ( 13214388 )
1954
11
Chronic congenital aregenerative anemia (pure red-cell anemia) associated with iso-immunization by the blood. ( 18129754 )
1949

Variations for Aregenerative Anemia

Expression for Aregenerative Anemia

Search GEO for disease gene expression data for Aregenerative Anemia.

Pathways for Aregenerative Anemia

GO Terms for Aregenerative Anemia

Sources for Aregenerative Anemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....